codeine phosphate; phenylephrine hydrochloride; promethazine hydrochloride
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
Phenergan VC w/ Codeine is a fixed-dose combination oral syrup containing codeine phosphate (opioid antitussive), phenylephrine hydrochloride (decongestant), and promethazine hydrochloride (antihistamine/anticholinergic). It is indicated for symptomatic relief of cough and upper respiratory congestion in patients with colds or allergies. The combination works via multiple mechanisms: codeine suppresses cough reflex centrally, phenylephrine reduces nasal congestion via alpha-1 adrenergic agonism, and promethazine provides antihistamine and sedating effects.
Product approaching loss of exclusivity with moderate competitive pressure (30/100); team likely focused on transition planning and retention strategies.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on Phenergan VC w/ Codeine offers limited career growth due to its LOE-approaching status and minimal linked job openings; opportunities are primarily defensive and operational (compliance, generics transition, market maintenance). Assignment to this product is typically a supporting or rotational role rather than a high-visibility career accelerator.
Worked on PHENERGAN VC W/ CODEINE at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.